CD21 Antibody (BU32): sc-52464

CD21 Antibody (BU32) is a mouse monoclonal IgG1 antibody that detects CD21 in human samples through immunofluorescence (IF) and flow cytometry (FCM) applications. CD21, also known as complement receptor type 2, is a type I integral membrane glycoprotein that plays a crucial role in the immune system by serving as a receptor for the C3d complement fragment and the Epstein-Barr virus. CD21 is primarily located on the surface of mature B cells, follicular dendritic cells, and certain epithelial cells, where CD21 is essential for B cell activation and proliferation. CD21 on B cells enhances their response to foreign antigens by modulating the strength of B cell antigen receptor signals in conjunction with the co-receptor CD19. This interaction is vital for the adaptive immune response, as CD21 ensures that B cells can effectively recognize and respond to pathogens while maintaining a regulated response to prevent overactivation. Additionally, CD21 undergoes phosphorylation following B cell activation, further influencing CD21′s function and the overall immune response. Anti-CD21 antibody (BU32) is an invaluable tool for researchers studying B cell biology and the mechanisms of immune regulation.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD21 Antibody (BU32) References:

1. Role of complement receptors CD21/CD35 in B lymphocyte activation and survival.  |  Carroll, M. 1999. Curr Top Microbiol Immunol. 246: 63-8; discussion 69. PMID: 10396040
2. Signaling by the CD19/CD21 complex on B cells.  |  Carter, RH. and Barrington, RA. 2004. Curr Dir Autoimmun. 7: 4-32. PMID: 14719373
3. Complement receptors CD21 and CD35 in humoral immunity.  |  Roozendaal, R. and Carroll, MC. 2007. Immunol Rev. 219: 157-66. PMID: 17850488
4. CD21 and FCRL5 form a receptor complex with robust B-cell activating capacity.  |  Franco, A., et al. 2018. Int Immunol. 30: 569-578. PMID: 30107486
5. CD21-/low B cells associate with joint damage in rheumatoid arthritis patients.  |  Thorarinsdottir, K., et al. 2019. Scand J Immunol. 90: e12792. PMID: 31141193
6. CD21 (Complement Receptor 2) Is the Receptor for Epstein-Barr Virus Entry into T Cells.  |  Smith, NA., et al. 2020. J Virol. 94: PMID: 32238579
7. CD21low B cells are predictive markers of new digital ulcers in systemic sclerosis.  |  Visentini, M., et al. 2021. Clin Exp Immunol. 205: 128-134. PMID: 33876421
8. Tumor-intrinsic CD21 expression impacts the response of B-cell malignancy cells to CD19-CAR-T cells.  |  Li, D., et al. 2022. J Leukoc Biol. 112: 913-918. PMID: 35338522
9. Multiparameter analysis of human B lymphocytes identifies heterogeneous CD19+ CD21lo subsets.  |  Wilfong, EM., et al. 2023. Cytometry A. 103: 283-294. PMID: 36281747
10. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity.  |  Tedder, TF., et al. 1997. Immunity. 6: 107-18. PMID: 9047233

The preferred CD21 antibody is CD21 Antibody (A-3): sc-13135.